These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 16700890

  • 1. Antisense oligonucleotides: from design to therapeutic application.
    Chan JH, Lim S, Wong WS.
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
    [Abstract] [Full Text] [Related]

  • 2. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C, Pei J, Kumar D, Sakabe I, Boudreau HE, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT, Parkinson DR.
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [Abstract] [Full Text] [Related]

  • 4. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y, Duan M, Lin R, Wang D, Li C, Bo X, Wang S.
    Mol Vis; 2006 Nov 13; 12():1364-71. PubMed ID: 17149362
    [Abstract] [Full Text] [Related]

  • 5. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R.
    Wien Klin Wochenschr; 1997 Jan 31; 109(2):40-6. PubMed ID: 9123943
    [Abstract] [Full Text] [Related]

  • 6. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A, Vlassov AV.
    Med Sci Monit; 2006 Apr 31; 12(4):RA67-74. PubMed ID: 16572063
    [Abstract] [Full Text] [Related]

  • 7. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M, Hayes CS, Chappell A, Murray SF, Yaksh TL, Hua XY.
    Neuroscience; 2005 Apr 31; 131(3):705-15. PubMed ID: 15730875
    [Abstract] [Full Text] [Related]

  • 8. Toxicology of antisense therapeutics.
    Jason TL, Koropatnick J, Berg RW.
    Toxicol Appl Pharmacol; 2004 Nov 15; 201(1):66-83. PubMed ID: 15519609
    [Abstract] [Full Text] [Related]

  • 9. Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design.
    Delihas N, Rokita SE, Zheng P.
    Nat Biotechnol; 1997 Aug 15; 15(8):751-3. PubMed ID: 9255788
    [Abstract] [Full Text] [Related]

  • 10. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI, Cheng K, Guntaka RV.
    Expert Opin Drug Deliv; 2005 Jan 15; 2(1):3-28. PubMed ID: 16296732
    [Abstract] [Full Text] [Related]

  • 11. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
    Zhao X, Pan F, Holt CM, Lewis AL, Lu JR.
    Expert Opin Drug Deliv; 2009 Jul 15; 6(7):673-86. PubMed ID: 19552611
    [Abstract] [Full Text] [Related]

  • 12. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA.
    Clin Cancer Res; 2006 Aug 15; 12(16):4940-8. PubMed ID: 16914583
    [Abstract] [Full Text] [Related]

  • 13. Antisense therapy in oncology: new hope for an old idea?
    Tamm I, Dörken B, Hartmann G.
    Lancet; 2001 Aug 11; 358(9280):489-97. PubMed ID: 11513935
    [Abstract] [Full Text] [Related]

  • 14. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
    Liu Y, Franzen S.
    Bioconjug Chem; 2008 May 11; 19(5):1009-16. PubMed ID: 18393455
    [Abstract] [Full Text] [Related]

  • 15. Antisense effects in the cell nucleus: modification of splicing.
    Kole R, Sazani P.
    Curr Opin Mol Ther; 2001 Jun 11; 3(3):229-34. PubMed ID: 11497345
    [Abstract] [Full Text] [Related]

  • 16. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
    Opalinska JB, Kalota A, Gifford LK, Lu P, Jen KY, Pradeepkumar PI, Barman J, Kim TK, Swider CR, Chattopadhyaya J, Gewirtz AM.
    Nucleic Acids Res; 2004 Jun 11; 32(19):5791-9. PubMed ID: 15514112
    [Abstract] [Full Text] [Related]

  • 17. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis.
    Dong L, Zuo L, Xia S, Gao S, Zhang C, Chen J, Zhang J.
    J Gene Med; 2009 Mar 11; 11(3):229-39. PubMed ID: 19189285
    [Abstract] [Full Text] [Related]

  • 18. Hybridization of antisense reagents to RNA.
    Sohail M, Southern EM.
    Curr Opin Mol Ther; 2000 Jun 11; 2(3):264-71. PubMed ID: 11249620
    [Abstract] [Full Text] [Related]

  • 19. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS, Wengel J.
    Curr Opin Drug Discov Devel; 2004 Mar 11; 7(2):188-94. PubMed ID: 15603252
    [Abstract] [Full Text] [Related]

  • 20. A dynamical systems model to simulate the perturbation kinetics of gene expression by antisense oligonucleotides.
    Fennell DA, Cotter FE.
    J Theor Biol; 2001 Mar 07; 209(1):103-12. PubMed ID: 11237574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.